Clinical trial Recruiting at 1 site Interventional Ages 13 to 21

Remote problem-solving program for autistic teens and their caregiver

Official title: The Effect of Dyadic Metacognitive Strategy Training in Autistic Youth or Young Adults and a Primary Caregiver

Run by University of Missouri-Columbia · NCT07216196 · Data updated 2026-11-12

This project will test a remote problem‑solving program (PREP) for autistic adolescents and young adults ages 13–21 together with a primary caregiver to help with independence and transition skills.

Quick facts

Study typeInterventional
Ages13 Years to 21 Years
SexAll
Enrollment24 (estimated)
SponsorUniversity of Missouri-Columbia
Academic / other
Locations1 site (Columbia, Missouri)
StatusRecruiting
StartedApril 8, 2026
Main results expectedNovember 3, 2026
Study endsMay 3, 2027
Registry record updatedApril 28, 2026
Trial IDNCT07216196 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Autistic adolescents aged 13–21 who have at least one year remaining in high school, can engage in reciprocal conversation, and have a primary caregiver willing to participate are ideal candidates.

Probably not a fit

Those with severe or profound intellectual disability (IQ <35), severe mental health conditions that prevent participation, or already enrolled in overlapping community transition services may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial delivers PREP, a metacognitive problem‑solving and environmental‑modification intervention, remotely to dyads of autistic adolescents or young adults and a primary caregiver. Participants set family‑chosen goals and work with clinicians on activity or environment changes rather than isolated skill drills. The study primarily measures feasibility and acceptability and includes limited efficacy testing on participation, health, and transition outcomes, using a waitlist crossover design. Sessions are conducted remotely and outcomes are measured by standardized participation and well‑being instruments.

Why it matters

Potential benefit: If successful, the program could improve day‑to‑day independence, participation, and smoother transitions to adulthood for autistic youth and reduce caregiver burden.

How similar studies have gone: PREP has shown improvements in activity performance and participation for youths with physical disabilities and autistic children ages 6–12, but it has not been rigorously tested in autistic adolescents or young adults.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Autistic adolescents aged 13-21 AND one primary parent, guardian, or caregiver aged 18 or older
* At least one year remaining in high school
* Ability to engage in reciprocal conversation
* Ability to provide informed consent/assent as part of an adapted procedure designed to prevent coercion and protect the rights of autistic adolescents with or without intellectual disability

Exclusion Criteria:

* Severe or profound intellectual disability (IQ\<35)
* Severe mental health conditions that interfere with ability to participate in the intervention
* Currently enrolled in community-based transition services redundant with remote PREP

Where it's running

  • University of Missouri - Columbia
    Columbia, Missouri, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.